miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes
- PMID: 29173002
- DOI: 10.2217/pgs-2017-0115
miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes
Abstract
Aim: Previous observations have implicated miR-509-3p's ability in regulating cisplatin-triggered apoptosis in ovarian cancer. However, the underlying mechanisms were not fully understood.
Materials & methods: The roles of miR-509-3p in cellular apoptosis were assessed through MTT and DAPI assays. The confirmation of the regulation of BCL2 family members by miR-509-3p was investigated by luciferase reporter assay, western blot, quantitative real-time PCR and rescue experiments.
Results: MiR-509-3p can decrease the IC50 values of cisplatin and promote apoptosis in ovarian cancer cells. Furthermore, on a panel of anti-apoptotic proteins, we identified that miR-509-3p could regulate BCL2, BCL2L2 and MCL1 via their 3'UTRs.
Conclusion: Our study demonstrates that miR-509-3p could sensitize ovarian cancer cells to cisplatin treatment by targeting multiple anti-apoptosis genes including BCL2.
Keywords: BCL2; apoptosis; microRNA-509-3p; ovarian cancer.
Similar articles
-
miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.Biochem Pharmacol. 2019 Mar;161:98-112. doi: 10.1016/j.bcp.2019.01.009. Epub 2019 Jan 11. Biochem Pharmacol. 2019. PMID: 30639456
-
MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis.Pharmacogenomics. 2016 Feb;17(3):187-97. doi: 10.2217/pgs.15.166. Epub 2016 Jan 20. Pharmacogenomics. 2016. PMID: 26786897
-
Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.Oncotarget. 2016 Jun 14;7(24):36321-36337. doi: 10.18632/oncotarget.9216. Oncotarget. 2016. PMID: 27166999 Free PMC article.
-
Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members.Int J Mol Sci. 2018 Jan 20;19(1):308. doi: 10.3390/ijms19010308. Int J Mol Sci. 2018. PMID: 29361709 Free PMC article. Review.
-
Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review).Int J Mol Med. 2020 Oct;46(4):1255-1265. doi: 10.3892/ijmm.2020.4689. Epub 2020 Jul 29. Int J Mol Med. 2020. PMID: 32945348 Free PMC article. Review.
Cited by
-
LncRNA ASAP1-IT1 enhances cancer cell stemness via regulating miR-509-3p/YAP1 axis in NSCLC.Cancer Cell Int. 2021 Oct 29;21(1):572. doi: 10.1186/s12935-021-02270-7. Cancer Cell Int. 2021. PMID: 34715859 Free PMC article.
-
Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.Front Immunol. 2021 Apr 1;12:641937. doi: 10.3389/fimmu.2021.641937. eCollection 2021. Front Immunol. 2021. PMID: 33868274 Free PMC article. Review.
-
BCL-w: apoptotic and non-apoptotic role in health and disease.Cell Death Dis. 2020 Apr 21;11(4):260. doi: 10.1038/s41419-020-2417-0. Cell Death Dis. 2020. PMID: 32317622 Free PMC article. Review.
-
MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.J Ovarian Res. 2021 Sep 30;14(1):127. doi: 10.1186/s13048-021-00882-1. J Ovarian Res. 2021. PMID: 34593006 Free PMC article. Review.
-
Mir-509-3p targets SLC25A13 to regulate ferroptosis and protect retinal endothelial cells in diabetic retinopathy.Acta Diabetol. 2024 Nov 7. doi: 10.1007/s00592-024-02400-3. Online ahead of print. Acta Diabetol. 2024. PMID: 39508857
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
